|
MXPA06002567A
(es)
|
2003-09-06 |
2006-09-04 |
Vertex Pharma |
Moduladores de transportadores con casete de union de atp.
|
|
RU2006120549A
(ru)
*
|
2003-11-14 |
2007-12-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты
|
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
CN101891680B
(zh)
|
2004-06-24 |
2014-10-29 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
|
ATE512145T1
(de)
*
|
2005-08-11 |
2011-06-15 |
Vertex Pharma |
Modulatoren des cystic fibrosis transmembrane conductance regulators
|
|
EP2774925B1
(en)
|
2005-11-08 |
2016-12-28 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic modulators of ATP-binding cassette transporters
|
|
DK3219705T3
(da)
|
2005-12-28 |
2020-04-14 |
Vertex Pharma |
Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
|
|
AU2006336504C9
(en)
|
2005-12-28 |
2015-05-14 |
Vertex Pharmaceuticals Incorporated |
1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
|
|
US7671221B2
(en)
*
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
US7776905B2
(en)
|
2006-04-07 |
2010-08-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
|
USRE50453E1
(en)
|
2006-04-07 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
|
WO2008141119A2
(en)
|
2007-05-09 |
2008-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of cftr
|
|
WO2009038913A2
(en)
|
2007-08-24 |
2009-03-26 |
Vertex Pharmaceuticals Incorporated |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
|
EP2211956A4
(en)
|
2007-10-10 |
2014-07-09 |
Parion Sciences Inc |
DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA
|
|
HRP20140103T1
(hr)
|
2007-11-16 |
2014-05-09 |
Vertex Pharmaceuticals Inc. |
Izokinolinski modulatori transportera atp-vežuä†e kazete
|
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
|
PL2231606T3
(pl)
*
|
2007-12-07 |
2013-07-31 |
Vertex Pharma |
Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
|
|
HUE031913T2
(en)
*
|
2007-12-07 |
2017-08-28 |
Vertex Pharma |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
|
US20090176839A1
(en)
*
|
2007-12-07 |
2009-07-09 |
Ali Keshavarz-Shokri |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
JP5523352B2
(ja)
|
2008-02-28 |
2014-06-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
|
|
DK2615085T3
(en)
|
2008-03-31 |
2015-10-05 |
Vertex Pharma |
Pyridyl derivatives as CFTR modulators
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
AU2009296271A1
(en)
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
TWI465449B
(zh)
*
|
2008-10-23 |
2014-12-21 |
Vertex Pharma |
囊腫性纖維化跨膜傳導調節因子之調控因子
|
|
EP2382197B1
(en)
|
2008-12-30 |
2016-10-05 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
KR101727762B1
(ko)
|
2009-03-20 |
2017-04-17 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
|
RS62767B1
(sr)
|
2010-04-07 |
2022-01-31 |
Vertex Pharma |
Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena
|
|
NZ602795A
(en)
|
2010-04-07 |
2015-01-30 |
Vertex Pharma |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
CN105130948A
(zh)
|
2010-04-22 |
2015-12-09 |
弗特克斯药品有限公司 |
制备环烷基甲酰胺基-吲哚化合物的方法
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
CN102675280B
(zh)
*
|
2011-03-09 |
2015-01-14 |
中国科学院上海有机化学研究所 |
含三氟甲基的吲哚酮类化合物及其制备方法和应用
|
|
WO2012125324A1
(en)
*
|
2011-03-14 |
2012-09-20 |
3M Innovative Properties Company |
Nanostructured articles
|
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
|
US8778383B2
(en)
|
2011-06-07 |
2014-07-15 |
Parion Sciences, Inc. |
Methods of treatment
|
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
|
RU2640420C2
(ru)
|
2011-11-08 |
2018-01-09 |
Вертекс Фармасьютикалз Инкорпорейтед |
Модуляторы транспортеров атф-связывающей кассеты
|
|
MX355183B
(es)
|
2012-01-25 |
2018-04-09 |
Vertex Pharma |
Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico.
|
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
薬学的組成物およびその投与
|
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CA2872029A1
(en)
|
2012-05-29 |
2013-12-05 |
Parion Sciences, Inc. |
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
|
|
CA2878057A1
(en)
|
2012-07-16 |
2014-01-23 |
Rossitza Gueorguieva Alargova |
Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
CA2896686A1
(en)
|
2012-12-17 |
2014-06-26 |
Parion Sciences, Inc. |
3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
|
|
PE20151054A1
(es)
|
2012-12-17 |
2015-08-07 |
Parion Sciences Inc |
Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales
|
|
MX2015007797A
(es)
|
2012-12-17 |
2015-10-05 |
Parion Sciences Inc |
Compuestos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil) carbamimidoil) pirazin-2-carboxamida.
|
|
HRP20210516T2
(hr)
|
2013-11-12 |
2021-10-01 |
Vertex Pharmaceuticals Incorporated |
Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
|
|
JP6543268B2
(ja)
|
2014-04-15 |
2019-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
|
|
JP2016017049A
(ja)
*
|
2014-07-08 |
2016-02-01 |
国立研究開発法人国立長寿医療研究センター |
新規ベンズオキサジン誘導体及びこれを含有する医薬
|
|
RS60906B1
(sr)
|
2014-10-06 |
2020-11-30 |
Vertex Pharma |
Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
|
|
CN107250113B
(zh)
|
2014-10-07 |
2019-03-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节蛋白的调节剂的共晶
|
|
US9567322B2
(en)
|
2014-10-31 |
2017-02-14 |
Abbvie S.Á.R.L. |
Substituted tetrahydropyrans and method of use
|
|
KR102576006B1
(ko)
|
2014-11-18 |
2023-09-06 |
버텍스 파마슈티칼스 인코포레이티드 |
고처리량 시험 고성능 액체 크로마토그래피의 수행 방법
|
|
KR20180029204A
(ko)
|
2015-06-02 |
2018-03-20 |
애브비 에스.에이.알.엘. |
치환된 피리딘 및 사용 방법
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
PL3359541T3
(pl)
|
2015-10-09 |
2021-01-11 |
AbbVie Overseas S.à r.l. |
N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
|
|
EP3359539A1
(en)
|
2015-10-09 |
2018-08-15 |
AbbVie S.À.R.L. |
Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
|
|
AU2017256172A1
(en)
|
2016-04-26 |
2018-09-06 |
AbbVie S.à.r.l. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
MX385064B
(es)
|
2016-05-12 |
2025-03-11 |
Res Triangle Inst |
Fenitelaminas vinílogas como liberadores de neurotransmisores.
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
PT3551622T
(pt)
|
2016-12-09 |
2020-11-12 |
Vertex Pharma |
Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
|
|
WO2018116185A1
(en)
|
2016-12-20 |
2018-06-28 |
AbbVie S.à.r.l. |
Deuterated cftr modulators and methods of use
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
US11253509B2
(en)
|
2017-06-08 |
2022-02-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
WO2019018395A1
(en)
|
2017-07-17 |
2019-01-24 |
Vertex Pharmaceuticals Incorporated |
METHODS OF TREATING CYSTIC FIBROSIS
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
CA3085006A1
(en)
|
2017-12-08 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2019193062A1
(en)
|
2018-04-03 |
2019-10-10 |
Abbvie S.Á.R.L |
Substituted pyrrolidines and their use
|
|
WO2020048826A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
|
|
US11345691B2
(en)
|
2019-06-03 |
2022-05-31 |
AbbVie Global Enterprises Ltd. |
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2021011327A1
(en)
|
2019-07-12 |
2021-01-21 |
Orphomed, Inc. |
Compound for treating cystic fibrosis
|
|
CA3157798A1
(en)
|
2019-11-12 |
2021-05-20 |
Zhongli Gao |
6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
|
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
US12324802B2
(en)
|
2020-11-18 |
2025-06-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022150173A1
(en)
|
2021-01-06 |
2022-07-14 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
EP4274828A1
(en)
|
2021-01-06 |
2023-11-15 |
AbbVie Global Enterprises Ltd. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
|
EP4396179A1
(en)
|
2021-09-03 |
2024-07-10 |
Genzyme Corporation |
Indole compounds and methods of use
|
|
AU2023338225A1
(en)
|
2022-09-07 |
2025-03-20 |
Genzyme Corporation |
Macrocyclic compounds, compositions, and methods of using thereof
|
|
WO2024054851A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocyclic compounds, compositions and methods of using thereof
|
|
WO2024054845A1
(en)
|
2022-09-07 |
2024-03-14 |
Sionna Therapeutics |
Macrocycic compounds, compositions, and methods of using thereof
|
|
WO2025132358A1
(en)
|
2023-12-21 |
2025-06-26 |
Galapagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
|